Ascendis Pharma (ASND) Q3 2026 earnings review
Ascendis profit jumps, but new U.S. Yorvipath patients hold steady
Ascendis Pharma, the Danish maker of drugs for rare hormone disorders, now turns fast sales gains into cash. Yorvipath, its hormone treatment for adults, more than doubled sales from a year ago, to €291 million. Operating cash reached €189 million, above what its own yearly plan pointed to. Ascendis therefore lifted that plan to at least €600 million.
| Product sales | €366M +89% from a year ago |
|---|---|
| Operating profit excluding one-offs, share of revenue | 42% 19% a year ago |
| Yuviwel sales | €16M €7.6M last quarter |
| Full-year operating cash outlook | Raised to at least €600M more than €500M before |
⚖️ Verdict: 🟢 Bullish
The story got better because the higher cash plan comes from the business, and Ascendis's second drug keeps adding patients. Yuviwel, for children with achondroplasia, doubled sales from last quarter and won a European advisory committee's backing. The bad news: Ascendis says new U.S. demand for Yorvipath only matched earlier quarters, so its yearly growth keeps slowing.
The question now is whether Yuviwel can keep growing while rival BioMarin challenges it over patents at the U.S. trade commission. A quiet ending lets Yuviwel add growth beside Yorvipath; a U.S. import ban would take it away. The commission's final ruling will settle it.
🐂 Bull Case
Spending Fell as a Share of Revenue
Ascendis now keeps 42 cents of operating profit, excluding one-offs, from each euro of revenue, against about 19 cents a year ago. Two cost lines did most of the work: selling and administration, which pays for sales teams and launches, and research and development.
- Selling and administration: 39.7% of revenue, down 13.4 percentage points from a year ago
- Research and development: 18.9% of revenue, down 12.4 percentage points
- Selling and administration in euros: €147 million, against €173 million last quarter
Yorvipath, its hormone treatment for adults with hypoparathyroidism, explains the yearly gain, because its sales grew far faster than the cost of the teams selling it. Selling costs still rose €33 million from a year ago, which Ascendis tied to "continued commercial expansion, including global launch activities". But the release gives no reason for the drop since last quarter, so part of the jump may be timing.
What to watch: selling and administration costs in early 2027, when the drugmaker plans its first European launch of Yuviwel, its drug for children with achondroplasia, in Germany. A return toward last quarter's level would mean timing explained part of the gain.
Yuviwel Sales Doubled Before a European Decision
Yuviwel, a once-weekly drug that helps children with achondroplasia grow taller, went on sale in the U.S. in the second quarter. Its sales more than doubled from last quarter to €16 million.
- U.S. patient enrollments: about 340 by October 31, from more than 220 at July 31
- Enrollments approved for insurance payment: more than 80%, from more than 65%
Yuviwel gives Ascendis a second source of growth beside Yorvipath, its treatment for adults with hypoparathyroidism. A European advisory committee backed approval, so the drugmaker plans a German launch in early 2027. But new U.S. enrollments eased to about 40 a month since July, by our math, from about 50.
What to watch: the European Commission's final decision, which Ascendis expects in the fourth quarter. An on-time decision would let German sales start as planned.
Cash Target Raised as Buybacks Speed Up
Operating cash flow is the cash the business brings in. Ascendis's yearly plan already counted €158 million from selling a priority review voucher, a U.S. credit it won with the approval of Yuviwel, its drug for achondroplasia.
The drugmaker now expects "at least €600 million". Because the voucher sits in both the old and new targets, the raise comes from the business itself. One caution: without the voucher, the new target still trails the €500 million Ascendis set before the sale, by our math.
What to watch: full-year operating cash flow, and whether buybacks hold the pace of about $273 million spent since September 30, by our math. That pace would return much of the new cash to shareholders.
Combination Therapy Trial Started Ahead of Plan
Ascendis is testing Yuviwel, its drug for children with achondroplasia, together with Skytrofa, its weekly growth hormone. In a mid-stage trial, the drugmaker reported a "durable increase in healthy, proportional growth in children with achondroplasia". It also said "100% of the 21 enrolled children remain on therapy to date".
Ascendis then started the final-stage trial, called cAtCH, during the third quarter, before the fourth-quarter date it gave last quarter. It plans to finish enrolling in the second quarter of 2027. The start still came a year after the date it set in 2025, and the release does not explain that delay.
What to watch: cAtCH enrollment against that second-quarter 2027 target. Meeting it would show the programme now runs on its own schedule.
🐻 Bear Case
New U.S. Yorvipath Patients No Longer Rising
Yorvipath, Ascendis's hormone treatment for adults with hypoparathyroidism, provides about four fifths of product sales. Chief executive Jan Mikkelsen said the company is "well positioned to deliver durable long-term growth". Yet the release says U.S. "new patient demand was consistent with prior quarters", so quarterly U.S. starts no longer rise.
Yorvipath sales still reached €291 million, €39 million more than last quarter, because new patients join those already treated. But a steady intake adds the same number of patients to an ever larger base. That is why product sales growth from a year ago eased from 105% last quarter to 89%.
What to watch: a U.S. enrollment count, which the release no longer reports. A falling count would show that Mikkelsen's growth claim now rests on patients already treated.
Skytrofa Still Grows Only 4% Over Nine Months
Skytrofa is Ascendis's once-weekly growth hormone for children. Its first-half sales came in below the same period of 2025, so the older business looked stuck while Yorvipath, the newer hormone treatment for adults, carried the group.
The third quarter argued against that view. Skytrofa sales rose 17% from a year ago, to €59 million. Over nine months, though, they gained only 4%, and the drugmaker gave no reason for the swing.
This matters because one strong quarter does not yet outweigh a slow year. A final-stage trial called HighLiGHts, which tests Skytrofa in four more growth conditions, finishes enrolling only in the first half of 2027.
What to watch: fourth-quarter Skytrofa sales against €53 million a year ago. A third straight quarter of growth would show the base business has turned.
Risks this quarter didn't answer
Several standing risks for Ascendis got no new figures in the third-quarter release. Each stays open, and each needs one specific disclosure before it moves either way.
- Patent dispute with BioMarin at the U.S. trade commission over Yuviwel, the achondroplasia drug: no update; a ruling or a settlement would move it
- Yorvipath prices after discounts: still undisclosed; a sales-per-patient figure would move it
- Patients who stop taking Yorvipath: never quantified; a stop rate would move it
- Rival drugs such as eneboparatide, encaleret and BioMarin's long-acting CNP: no news in the release; a rival approval would move it
- Launches abroad: Ascendis said "new patient demand accelerated through new commercial launches" and Yorvipath now reaches more than 40 countries, from 35; a regional sales split would move it
👓 Other Themes
Ascendis Now Books a Tax Charge on Profit
Ascendis recognised €680 million of tax assets from earlier years in the first quarter, because it now expects taxable profits. Since then it records a tax charge against profit. The third-quarter charge reached €39 million, about 35% of pretax profit by our math. That is why net profit trails operating profit, and why profit excluding one-offs reads more cleanly.
💲 Other KPIs
Money owed by customers rose to €226 million, but only in step with sales. It equals about 61% of quarterly revenue, the same share as last quarter and below 63% a year ago. So Ascendis is not giving buyers longer to pay in order to lift sales.
Short-term provisions, money the drugmaker has set aside for payments it expects to make, climbed to €265 million. As a share of quarterly product sales they reached about 73%, from 70% last quarter. A year ago the share was 71%, so the ratio has moved little across four quarters.
Inventory of drugs rose to €331 million, up 7% from last quarter, while product sales climbed faster. Inventory now equals about 0.9 times a quarter's product sales, against 1.6 times a year ago. The group is selling through its stock faster, which frees cash.
🔮 Guidance
Raised. The plan now has Ascendis bringing in at least €600 million of operating cash this year. By our math, that leaves at least €137 million for the fourth quarter, well below the third quarter's €189 million. If the pattern holds, the year reaches about €652 million.
Unchanged. The company still expects the European Commission to rule on Yuviwel, its drug for children with achondroplasia, in the fourth quarter. The regulator's advisory committee has now recommended approval, so only the Commission's formal decision remains.
New. Ascendis plans its first European sales of Yuviwel in Germany in the first quarter of 2027, once the Commission approves the drug. It also expects revenue from several countries outside the U.S. and Europe in the coming quarters, through early access programmes.
New. The drugmaker expects main results in the third quarter of 2027 from its trial of Yuviwel in babies under two. One-year data from the first infants showed the drug "stabilized or improved foramen magnum stenosis", a narrowing of skull bone that can press on the spinal cord.
Unchanged. Ascendis still plans to enroll the first patients in its final-stage trial of TransCon CNP alone in children with hypochondroplasia this quarter, inside the second-half window it gave before.
New. The group plans to start a mid-stage trial of TransCon CNP in adults with achondroplasia in the fourth quarter, which would take the drug beyond children for the first time.
New. Ascendis expects to finish enrolling children in its final-stage trial of TransCon CNP plus TransCon hGH in the second quarter of 2027, after starting the trial in the third quarter.
New. The company expects to complete enrollment in the first half of 2027 for its final-stage trial of Skytrofa in four growth conditions, including Turner syndrome and short stature with no known cause.
❓ Key Questions
How many new U.S. patients started Yorvipath this quarter?
The release says U.S. demand matched earlier quarters but gives no count for a second quarter. Without it, readers cannot tell whether the base of treated patients still grows at the same pace.
What has the trade commission decided in the BioMarin case?
Yuviwel's U.S. sales depend on the outcome of BioMarin's patent claims. The release says nothing about the judge's initial ruling or possible remedies, such as an import ban or royalties.
Why did selling costs fall €26 million from last quarter?
The drop did much of the work behind the jump in the operating margin. If launch spending simply moved into later quarters, the European Yuviwel launch could reverse part of the gain.
How large will Yuviwel sales outside the U.S. be?
Ascendis expects revenue from countries outside the U.S. and Europe in the coming quarters but gives no size. A figure would show how much the European launch can add in 2027.
How many Yuviwel patients switched from BioMarin's Voxzogo?
Patients who switch from the rival drug widen the market less than first-time patients do. The split would show whether Yuviwel brings in new patients or mainly takes share.